Gsk (GSK) Non-Current Assets (2009 - 2026)
Gsk (GSK) posted Non-Current Assets of $58.0 billion for Q4 2025, up 6.42% on a QoQ basis from $54.5 billion in Q4 2024, and up 6.42% year-over-year from $54.5 billion in Q4 2024.
Gsk (GSK) has 10 years of Non-Current Assets data on file, last reported at $58.0 billion in Q4 2025.
- In Q4 2025, Non-Current Assets rose 6.42% year-over-year to $58.0 billion; the TTM figure through Dec 2025 stood at $58.0 billion (up 6.42% YoY), while the FY2025 annual figure was $58.0 billion, up 6.42% from the prior year.
- Non-Current Assets grew to $58.0 billion in Q4 2025, from $54.5 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $81.5 billion in Q4 2021 and bottomed at $46.2 billion in Q4 2022.
- A 5-year average of $58.1 billion and a median of $54.5 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 43.3% — and 2024, when it advanced 8.81%.
- Year by year, Non-Current Assets stood at $81.5 billion in 2021, then slumped by 43.3% to $46.2 billion in 2022, then grew by 8.46% to $50.1 billion in 2023, then advanced by 8.81% to $54.5 billion in 2024, then advanced by 6.42% to $58.0 billion in 2025.
- The last three Non-Current Assets figures came in at $58.0 billion (Q4 2025), $54.5 billion (Q4 2024), and $50.1 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 58.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.81 Bn |
| Dec 31, 2025 | 58.01 Bn |
| Sep 30, 2025 | 58.69 Bn |
| Jun 30, 2025 | 55.48 Bn |
| Mar 31, 2025 | 53.68 Bn |
| Dec 31, 2024 | 54.51 Bn |
| Sep 30, 2024 | 52.95 Bn |
| Jun 30, 2024 | 52.13 Bn |
| Mar 31, 2024 | 52.40 Bn |
| Dec 31, 2023 | 50.09 Bn |
| Sep 30, 2023 | 50.19 Bn |
| Jun 30, 2023 | 50.20 Bn |
| Mar 31, 2023 | 47.26 Bn |
| Dec 31, 2022 | 46.19 Bn |
| Sep 30, 2022 | 47.22 Bn |
| Jun 30, 2022 | 43.90 Bn |
| Mar 31, 2022 | 39.89 Bn |
| Dec 31, 2021 | 81.46 Bn |
| Sep 30, 2021 | 83.31 Bn |
| Jun 30, 2021 | 83.09 Bn |
| Mar 31, 2021 | 82.12 Bn |
| Dec 31, 2020 | 79.47 Bn |
| Jun 30, 2020 | 76.57 Bn |
| Mar 31, 2020 | 79.94 Bn |
| Dec 31, 2019 | 77.40 Bn |
| Sep 30, 2019 | 76.78 Bn |
| Jun 30, 2019 | 58.40 Bn |
| Mar 31, 2019 | 58.38 Bn |
| Dec 31, 2018 | 52.94 Bn |
| Sep 30, 2018 | 53.68 Bn |
| Jun 30, 2018 | 55.30 Bn |
| Mar 31, 2018 | 55.27 Bn |
| Dec 31, 2017 | 53.74 Bn |
| Sep 30, 2017 | 53.82 Bn |
| Jun 30, 2017 | 53.42 Bn |
| Mar 31, 2017 | 52.58 Bn |
| Dec 31, 2016 | 44.88 Bn |
| Sep 30, 2016 | 54.13 Bn |
| Jun 30, 2016 | 58.52 Bn |
| Mar 31, 2016 | 55.40 Bn |
| Dec 31, 2015 | 55.93 Bn |
| Sep 30, 2015 | 56.03 Bn |
| Jun 30, 2015 | 55.11 Bn |
| Mar 31, 2015 | 56.32 Bn |
| Dec 31, 2014 | 41.15 Bn |
| Sep 30, 2014 | 42.53 Bn |
| Jun 30, 2014 | 42.57 Bn |
| Mar 31, 2014 | 43.79 Bn |
| Dec 31, 2013 | 43.49 Bn |
| Sep 30, 2013 | 42.84 Bn |
| Jun 30, 2013 | 43.96 Bn |
| Mar 31, 2013 | 44.74 Bn |
| Dec 31, 2012 | 3.00 Bn |
| Sep 30, 2012 | 42.58 Bn |
| Jun 30, 2012 | 39.91 Bn |
| Mar 31, 2012 | 38.54 Bn |
| Dec 31, 2011 | 3.00 Bn |
| Sep 30, 2011 | 40.29 Bn |
| Jun 30, 2011 | 42.02 Bn |
| Mar 31, 2011 | 41.28 Bn |
| Dec 31, 2010 | 41.38 Bn |
| Sep 30, 2010 | 40.09 Bn |
| Jun 30, 2010 | 38.77 Bn |
| Mar 31, 2010 | 40.89 Bn |
| Dec 31, 2009 | 41.31 Bn |
| Sep 30, 2009 | 39.55 Bn |
| Jun 30, 2009 | 32.07 Bn |
| Mar 31, 2009 | 31.90 Bn |